NO20042148L - Cyklooksygenase-2 inhibitor/histondeacetylaseinhibitorkombinasjon - Google Patents

Cyklooksygenase-2 inhibitor/histondeacetylaseinhibitorkombinasjon

Info

Publication number
NO20042148L
NO20042148L NO20042148A NO20042148A NO20042148L NO 20042148 L NO20042148 L NO 20042148L NO 20042148 A NO20042148 A NO 20042148A NO 20042148 A NO20042148 A NO 20042148A NO 20042148 L NO20042148 L NO 20042148L
Authority
NO
Norway
Prior art keywords
inhibitor
combination
cyclooxygenase
histone deacetylase
relates
Prior art date
Application number
NO20042148A
Other languages
English (en)
Norwegian (no)
Inventor
Ying-Nan Pan Chen
Peter Lassota
Alexander Wallace Wood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20042148L publication Critical patent/NO20042148L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
NO20042148A 2001-11-06 2004-05-25 Cyklooksygenase-2 inhibitor/histondeacetylaseinhibitorkombinasjon NO20042148L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33301601P 2001-11-06 2001-11-06
US41931402P 2002-10-17 2002-10-17
PCT/EP2002/012343 WO2003039599A1 (en) 2001-11-06 2002-11-05 Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination

Publications (1)

Publication Number Publication Date
NO20042148L true NO20042148L (no) 2004-08-04

Family

ID=26988512

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042148A NO20042148L (no) 2001-11-06 2004-05-25 Cyklooksygenase-2 inhibitor/histondeacetylaseinhibitorkombinasjon

Country Status (22)

Country Link
US (3) US7402603B2 (de)
EP (1) EP1443967B1 (de)
JP (1) JP4413614B2 (de)
KR (1) KR100937064B1 (de)
CN (1) CN100457183C (de)
AT (1) ATE352319T1 (de)
AU (1) AU2002351844B2 (de)
BR (1) BR0213932A (de)
CA (1) CA2461373A1 (de)
CY (1) CY1106508T1 (de)
DE (1) DE60217895T2 (de)
DK (1) DK1443967T3 (de)
ES (1) ES2280597T3 (de)
HU (1) HUP0402370A3 (de)
IL (2) IL160970A0 (de)
MX (1) MXPA04004312A (de)
NO (1) NO20042148L (de)
NZ (1) NZ544689A (de)
PL (1) PL205853B1 (de)
PT (1) PT1443967E (de)
RU (1) RU2311200C2 (de)
WO (1) WO2003039599A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1608628A2 (de) * 2003-03-17 2005-12-28 Takeda San Diego, Inc. Inhibitoren der histondeacetylase
AR043850A1 (es) * 2003-04-17 2005-08-17 Bayer Pharmaceuticals Corp Acidos hidroxamicos utiles en el tratamiento de trastornos hiperproliferativos
WO2004103358A2 (en) * 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents
EP1491188A1 (de) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topische Verwendung von Valproinsäure zur Behandlung von Hauterkrankungen
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1780210A4 (de) * 2004-08-11 2009-06-10 Kyorin Seiyaku Kk Neues zyklisches aminobenzoesäurederivat
US7642275B2 (en) * 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7786330B2 (en) 2005-02-28 2010-08-31 Asahi Glass Company, Limited Process for producing 1,2-dialkoxy-3-fluorobenzene
EP1896436A2 (de) * 2005-05-11 2008-03-12 Takeda San Diego, Inc. Inhibitoren der histondeacetylase
AU2006270322A1 (en) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1743654A1 (de) * 2005-07-15 2007-01-17 TopoTarget Germany AG Verwendung von Histon Deacetylase-Hemmer zusammen mit NSAIDen zur Behandlung von Krebs und/oder Entzündungskrankheiten
WO2007016136A2 (en) * 2005-07-28 2007-02-08 Nitromed, Inc. Organic nitric oxide enhancing salts of cyclooxygenase-2 selective inhibitors, compositons and methods of use
JP2009525955A (ja) * 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CN102584673B (zh) * 2006-06-12 2014-08-06 诺华股份有限公司 N-羟基-3-[4-[[[2-(2-甲基-1h-吲哚-3-基)乙基]氨基]甲基]苯基]-2e-2-丙烯酰胺的多晶型物
EP2394991B1 (de) 2006-06-12 2015-09-23 Novartis AG Verfahren zur Herstellung von Ausgangsmaterialien für N-Hydroxy-3-[4-[2-(2-methyl-1H-indol-3-yl)ethylaminomethyl]-phenyl]-2E-2-propenamid
BRPI0713653A2 (pt) * 2006-06-12 2012-10-23 Novartis Ag processo para a preparação de sais de n-hidróxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil ]fenil]-2e-2propenamida
WO2008002634A1 (en) * 2006-06-28 2008-01-03 Novartis Ag Use of hdac inhibitors for the treatment of lymphomas
EP2055692A4 (de) * 2006-08-25 2010-07-07 Asahi Glass Co Ltd Verfahren zur herstellung von 1,2-dialkoxy-3-fluorbenzol
AU2008214299B2 (en) 2007-02-06 2014-01-09 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
EP2491923A3 (de) * 2007-02-15 2012-12-26 Novartis AG Kombinationen therapeutischer Wirkstoffe zur Krebsbehandlung
EA018618B1 (ru) 2007-10-01 2013-09-30 Ликсте Байотекнолоджи, Инк. Ингибиторы hdac
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
CA2730148C (en) 2008-08-01 2018-04-03 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
RU2640416C2 (ru) * 2012-04-16 2018-01-09 Тоа Эйо Лтд. Бициклическое соединение
EA201591931A1 (ru) 2013-04-09 2016-05-31 Ликсте Байотекнолоджи, Инк. Композиции оксабициклогептанов и оксабициклогептенов
US9745253B2 (en) 2015-03-13 2017-08-29 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
CN115108926B (zh) * 2022-04-02 2023-06-20 上海工程技术大学 一种用于制备厄达替尼的中间体化合物及制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)

Also Published As

Publication number Publication date
PL205853B1 (pl) 2010-06-30
NZ544689A (en) 2007-08-31
RU2004117170A (ru) 2005-04-20
DK1443967T3 (da) 2007-04-16
AU2002351844B2 (en) 2006-12-21
IL160970A (en) 2010-06-30
DE60217895D1 (en) 2007-03-15
BR0213932A (pt) 2004-08-31
US20080227845A1 (en) 2008-09-18
JP4413614B2 (ja) 2010-02-10
IL160970A0 (en) 2004-08-31
EP1443967A1 (de) 2004-08-11
PL368539A1 (en) 2005-04-04
HUP0402370A2 (hu) 2005-02-28
PT1443967E (pt) 2007-04-30
US20090192211A1 (en) 2009-07-30
JP2005510517A (ja) 2005-04-21
RU2311200C2 (ru) 2007-11-27
DE60217895T2 (de) 2007-07-05
ATE352319T1 (de) 2007-02-15
WO2003039599A1 (en) 2003-05-15
KR100937064B1 (ko) 2010-01-15
KR20050043744A (ko) 2005-05-11
US20050032899A1 (en) 2005-02-10
EP1443967B1 (de) 2007-01-24
US7402603B2 (en) 2008-07-22
CN1578674A (zh) 2005-02-09
CY1106508T1 (el) 2012-01-25
CN100457183C (zh) 2009-02-04
ES2280597T3 (es) 2007-09-16
CA2461373A1 (en) 2003-05-15
MXPA04004312A (es) 2005-05-16
HUP0402370A3 (en) 2008-04-28

Similar Documents

Publication Publication Date Title
ATE352319T1 (de) Kombination cyclooxygenase-2 inhibitor/ histone deacetylase inhibitor
MXPA05012464A (es) Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
DE60329316D1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
BR9914044A (pt) ésteres tetrahidropirido
ATE451369T1 (de) Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
ATE408601T1 (de) Fredericamycin-derivate
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
CY1109045T1 (el) Ρετινοειδη για τη θεραπεια του εμφυσηματος
WO2003106381A3 (en) ADAM 10 HUMAN INHIBITORS
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
ATE438618T1 (de) Inhibitoren von humanem adam-10
WO2007024574A3 (en) Topical formulations of histone deacetylase inhibitors and methods of using the same
BR9815596A (pt) Composto, composição farmacêutica, método de tratamento de doenças inflamatórias e método de tratamento de condição ou doença mediada por mmps e/ou tnf e/ou agrecanase
BR0307629A (pt) Métodos e composições para tratar condições hiperproliferativas
BR9611897A (pt) Benzofurano carboxamidas e sulfonamidas
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
HK1087010A1 (en) Use of a composition comprising vitamin k1 oxide or a derivative thereof for the treatment and/or the prevention of mammal dermatological lesions
WO2006128740A3 (en) Anti-vascular methods and therapies employing lysyl oxidase inhibitors
HUP0102322A2 (hu) Fehérje farnezil-transzferáz és HMG-CoA reduktáz inhibitorok kombinációi és alkalmazásuk rák kezelésére
ATE423102T1 (de) 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer
WO2005044301A3 (en) Use of specific histones for the treatment of parasitic diseases
DE602004008247D1 (de) Zusammensetzung die tamsulosin und ein nichtsteroides entzündungshemmendes mittel enthält
BR0212607A (pt) Agonistas retinóides ii de uréia substituìda
ECSP045071A (es) Combinacion de inhibidor de ciclooxigenasa-2/inhibidor de desacetilasa de histona
WO2008048117A3 (en) Synthesis of 5,6-dimethyl-9-oxo-9h-xanthen-4-yl- acetic acid (dmxaa)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application